AngioLab Inc
251280
Company Profile
Business description
AngioLab Inc is a biotechnology company. It is developing pharmaceuticals and health functional foods based on the inhibition of angiogenesis. The group is developing natural products and antibody-based pharmaceuticals.
Contact
65, 122, 159, Techno 3-ro
Yuseong-gu
Gwanpyeong-dong, Hanshin S Mecca
Daejeon
KORT: +82 428675785
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,263.46 | 57.39 | 0.70% |
| DAX 40 | 24,345.60 | 86.80 | 0.36% |
| Dow JONES (US) | 47,071.81 | 365.23 | 0.78% |
| FTSE 100 | 9,429.58 | 26.01 | 0.28% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,936.15 | 54.39 | -0.24% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,740.48 | 5.35 | 0.08% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |